Hostname: page-component-7b7567c8c-2jgqx Total loading time: 0 Render date: 2026-11-19T15:34:10.512Z Has data issue: false hasContentIssue false

Effectiveness of empiric carbapenem versus non-carbapenem therapy for extended-spectrum β-lactamase producing Enterobacterales infections in non-intensive care unit patients: a real-world investigation in a hospital with high-prevalence of extended-spectrum β-lactamase producing Enterobacterales

Published online by Cambridge University Press:  04 June 2024

Amy Y. Kang*
Affiliation:
Department of Pharmacy Practice, Chapman University School of Pharmacy, Irvine, CA, USADepartment of Pharmacy, Harbor-UCLA Medical Center, Torrance, CA, USADivision of Infectious Diseases, Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, USA
Mary Elkomos
Affiliation:
Department of Pharmacy Practice, Chapman University School of Pharmacy, Irvine, CA, USA
Danny Pham
Affiliation:
Department of Pharmacy, University of California Irvine Health, Orange, CA, USA
Michelle Guerrero
Affiliation:
Department of Pharmacy, Memorial Hermann-Texas Medical Center, Houston, TX, USA
Deborah Kupferwasser
Affiliation:
Division of Infectious Diseases, Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, USA
Loren G. Miller
Affiliation:
Division of Infectious Diseases, Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, USADivision of Infectious Diseases, Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA
*
Corresponding author: Amy Kang; Email: amkang@chapman.edu

Abstract

Objective:

To investigate whether empiric carbapenem therapy, compared to empiric non-carbapenem therapy, was associated with improved clinical outcomes among hospitalized, non-intensive care unit (ICU) patients with extended-spectrum β-lactamase (ESBL)-producing Enterobacterales infections.

Methods:

We performed a retrospective cohort study of adult, non-ICU patients admitted with ESBL-producing Enterobacterales infections. Primary outcome was time to clinical stability from the first empiric antibiotic dose. Secondary outcomes were early clinical response and 30-day all-cause hospital readmission. We used multivariate regression methods to examine time to clinical stability.

Results:

Of the 142 patients, 59 (42%) received empiric carbapenems and 83 (58%) received empiric non-carbapenems, most commonly ceftriaxone (49/83, 59%). Median age was 59 years. The most common infection source was urinary (71%). The carbapenem group had a higher proportion of patients who received antibiotics within 6 months of admission (55% vs 28%, P < .01) and history of ESBL (57% vs 17%, P < .01). There were no significant differences in hours until clinical stability between the carbapenem and non-carbapenem groups (22 (IQR: 0, 85) vs 19 (IQR: 0, 69), P = .54). Early clinical response (88% vs 90%, P = .79) and 30-day all-cause hospital readmission (17% vs 8%, P = .13) were similar between groups.

Conclusion:

Among hospitalized non-ICU patients with ESBL-producing Enterobacterales infection, we found no difference in time to clinical stability after the first empiric antibiotic dose between those receiving carbapenems and those who did not. Our data suggest that empiric carbapenem use may not be an important driver of clinical response in patients with less severe ESBL-producing Enterobacterales infection.

Information

Type
Original Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
Figure 0

Figure 1.Patient inclusion/exclusion and cohort allocation.

Figure 1

Table 1.Baseline characteristics and clinical presentations

Figure 2

Figure 2.Empiric therapy for ESBL-producing Enterobacterales in non-ICU settings. Abbreviations: ESBL, extended-spectrum beta-lactamase; PTZ, piperacillin-tazobactam; FQ, fluoroquinolones; SMX/TMP, sulfamethoxazole-trimethoprim. Note that some patients received more than one antibiotic as empiric therapy.

Figure 3

Table 2.Treatment

Figure 4

Figure 3.Directed therapy. Abbreviations: FQ, fluoroquinolones; SMX/TMP, sulfamethoxazole-trimethoprim; PTZ, piperacillin-tazobactam.

Figure 5

Table 3.Clinical outcomes

Figure 6

Figure 4.Kaplan–Meier plot of the proportion of patients who presented clinically unstable.